IN2012MN02262A - - Google Patents
Download PDFInfo
- Publication number
- IN2012MN02262A IN2012MN02262A IN2262MUN2012A IN2012MN02262A IN 2012MN02262 A IN2012MN02262 A IN 2012MN02262A IN 2262MUN2012 A IN2262MUN2012 A IN 2262MUN2012A IN 2012MN02262 A IN2012MN02262 A IN 2012MN02262A
- Authority
- IN
- India
- Prior art keywords
- multimeric protein
- disclosed
- protein structures
- alpha
- terms
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 208000024720 Fabry Disease Diseases 0.000 abstract 1
- 102000005840 alpha-Galactosidase Human genes 0.000 abstract 1
- 108010030291 alpha-Galactosidase Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 230000002132 lysosomal effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
Abstract
Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein as well a process for preparing same and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30948710P | 2010-03-02 | 2010-03-02 | |
| PCT/IL2010/000956 WO2011061736A1 (en) | 2009-11-17 | 2010-11-17 | Alkaline alpha galactosidase for the treatment of fabry disease |
| US201161434499P | 2011-01-20 | 2011-01-20 | |
| US201161434503P | 2011-01-20 | 2011-01-20 | |
| PCT/IL2011/000209 WO2011107990A1 (en) | 2010-03-02 | 2011-03-02 | Stabilized alpha-galactosidase and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012MN02262A true IN2012MN02262A (en) | 2015-06-12 |
Family
ID=44121635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2262MUN2012 IN2012MN02262A (en) | 2010-03-02 | 2011-03-02 |
Country Status (23)
| Country | Link |
|---|---|
| EP (3) | EP2865751B1 (en) |
| JP (2) | JP5758920B2 (en) |
| KR (1) | KR101928403B1 (en) |
| CN (1) | CN102933707B (en) |
| AU (1) | AU2011222452B2 (en) |
| BR (2) | BR122014021216A2 (en) |
| CA (1) | CA2791461C (en) |
| DK (1) | DK2865751T3 (en) |
| ES (2) | ES2606532T3 (en) |
| FI (1) | FIC20230032I1 (en) |
| FR (1) | FR23C1041I2 (en) |
| HR (1) | HRP20200428T1 (en) |
| HU (2) | HUE030959T2 (en) |
| IL (2) | IL221741A (en) |
| IN (1) | IN2012MN02262A (en) |
| NL (1) | NL301249I2 (en) |
| NO (1) | NO2023041I1 (en) |
| NZ (2) | NZ623294A (en) |
| PL (1) | PL2865751T3 (en) |
| SG (2) | SG183558A1 (en) |
| SI (1) | SI2865751T1 (en) |
| WO (1) | WO2011107990A1 (en) |
| ZA (1) | ZA201206725B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| SI2865751T1 (en) * | 2010-03-02 | 2017-01-31 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| KR101883803B1 (en) * | 2011-01-20 | 2018-07-31 | 프로탈릭스 리미티드 | Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells |
| TWI793159B (en) * | 2013-10-23 | 2023-02-21 | 美商健臻公司 | Recombinant glycoproteins and uses thereof |
| LT3237621T (en) * | 2014-12-22 | 2023-09-25 | Codexis, Inc. | Human alpha-galactosidase variants |
| WO2016116966A1 (en) * | 2015-01-22 | 2016-07-28 | Jcr Pharmaceuticals Co., Ltd. | Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins |
| WO2016146760A1 (en) | 2015-03-17 | 2016-09-22 | Greenovation Biotech Gmbh | Glycosylated lysosomal proteins, method of production and uses |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| WO2018127920A1 (en) * | 2017-01-05 | 2018-07-12 | Protalix Ltd. | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
| US11517613B2 (en) * | 2017-06-07 | 2022-12-06 | Amano Enzyme Inc. | Lactase bulk powder and lactase preparation |
| AU2019403323B2 (en) | 2018-12-20 | 2026-02-26 | Codexis, Inc. | Human alpha-galactosidase variants |
| CA3173294A1 (en) * | 2020-02-28 | 2021-09-02 | Codexis, Inc. | Human alpha-galactosidase variants |
| MX2023005235A (en) | 2020-11-03 | 2023-10-16 | Protalix Ltd | Modified uricase and uses thereof. |
| CN112176026A (en) * | 2020-11-06 | 2021-01-05 | 诺道中科(北京)生物科技有限公司 | Detection kit for alpha-galactosidase activity |
| CN116254287B (en) * | 2022-11-24 | 2024-06-04 | 西北农林科技大学 | Application of corn ZmAGA3 gene in improving drought tolerance of plants |
| CN118243646B (en) * | 2024-04-24 | 2025-01-24 | 武汉简为医疗科技有限公司 | A lactose intolerance detection kit and its use method |
| JP7745040B1 (en) | 2024-06-21 | 2025-09-26 | デンカ株式会社 | Method for recovering and producing target protein |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| CA2052728A1 (en) | 1991-10-03 | 1993-04-04 | Guy Ampleman | Glycidyl azide polymer |
| US6329191B1 (en) * | 1993-08-30 | 2001-12-11 | Hawaii Biotechnology Group, Inc. | DNA encoding recombinant coffee bean alpha-galactosidase |
| US6458574B1 (en) * | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US20050032211A1 (en) * | 1996-09-26 | 2005-02-10 | Metabogal Ltd. | Cell/tissue culturing device, system and method |
| DE69839563D1 (en) * | 1997-09-05 | 2008-07-10 | Altus Pharmaceuticals Inc | CARBOHYDRATE-NETWORKED GLYCOPROTEIN CRYSTALS |
| IL125423A (en) | 1998-07-20 | 2004-08-31 | Israel State | Alkaline alpha-galactosidase having broad substrate specificity |
| DE60022336T2 (en) * | 1999-04-02 | 2006-06-22 | Ajinomoto Co., Inc. | METHOD FOR PRODUCING PEPTIDE SUBUNITS FROM POLYMER PROTEINS |
| DK1523548T3 (en) | 2002-05-15 | 2010-05-10 | Agricultural Res Org | Polynucleotide Sequences Encoding Alkaline Alpha-Galactosidases and Methods for Using Them |
| US7951557B2 (en) * | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
| EP1877099B1 (en) * | 2005-04-06 | 2012-09-19 | Genzyme Corporation | Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety |
| BRPI0618583A2 (en) * | 2005-11-18 | 2011-09-06 | Tokyo Metropolitan Org Med Res | highly functional enzyme having modified substrate specificity |
| WO2008075957A1 (en) | 2006-12-21 | 2008-06-26 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Treatment of fabry disease |
| JP2008169195A (en) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | Insulin secretory peptide drug conjugates using carrier substances |
| EP1955712A1 (en) * | 2007-02-09 | 2008-08-13 | Scil proteins GmbH | Multimeric conjugate |
| CA2696699A1 (en) | 2007-08-20 | 2009-02-26 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
| SI2865751T1 (en) * | 2010-03-02 | 2017-01-31 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
-
2011
- 2011-03-02 SI SI201131048A patent/SI2865751T1/en unknown
- 2011-03-02 SG SG2012064580A patent/SG183558A1/en unknown
- 2011-03-02 IN IN2262MUN2012 patent/IN2012MN02262A/en unknown
- 2011-03-02 ES ES14195875.1T patent/ES2606532T3/en active Active
- 2011-03-02 NZ NZ623294A patent/NZ623294A/en unknown
- 2011-03-02 KR KR1020127025725A patent/KR101928403B1/en active Active
- 2011-03-02 DK DK14195875.1T patent/DK2865751T3/en active
- 2011-03-02 PL PL14195875T patent/PL2865751T3/en unknown
- 2011-03-02 EP EP14195875.1A patent/EP2865751B1/en active Active
- 2011-03-02 EP EP16173953.7A patent/EP3088514B1/en active Active
- 2011-03-02 ES ES16173953T patent/ES2708843T3/en active Active
- 2011-03-02 BR BR122014021216-0A patent/BR122014021216A2/en active IP Right Grant
- 2011-03-02 AU AU2011222452A patent/AU2011222452B2/en active Active
- 2011-03-02 HU HUE14195875A patent/HUE030959T2/en unknown
- 2011-03-02 BR BR112012022029-2A patent/BR112012022029B1/en active IP Right Grant
- 2011-03-02 CA CA2791461A patent/CA2791461C/en active Active
- 2011-03-02 CN CN201180022145.6A patent/CN102933707B/en active Active
- 2011-03-02 WO PCT/IL2011/000209 patent/WO2011107990A1/en not_active Ceased
- 2011-03-02 SG SG10201502609QA patent/SG10201502609QA/en unknown
- 2011-03-02 NZ NZ602317A patent/NZ602317A/en unknown
- 2011-03-02 JP JP2012555542A patent/JP5758920B2/en active Active
- 2011-03-02 EP EP11712340.6A patent/EP2542675B1/en active Active
-
2012
- 2012-09-02 IL IL221741A patent/IL221741A/en active IP Right Grant
- 2012-09-07 ZA ZA2012/06725A patent/ZA201206725B/en unknown
-
2014
- 2014-08-06 JP JP2014160449A patent/JP5871999B2/en active Active
-
2017
- 2017-06-29 IL IL253249A patent/IL253249B/en active IP Right Grant
-
2020
- 2020-03-16 HR HRP20200428TT patent/HRP20200428T1/en unknown
-
2023
- 2023-10-31 HU HUS2300038C patent/HUS2300038I1/en unknown
- 2023-11-01 NO NO2023041C patent/NO2023041I1/en unknown
- 2023-11-01 NL NL301249C patent/NL301249I2/en unknown
- 2023-11-02 FR FR23C1041C patent/FR23C1041I2/en active Active
- 2023-11-02 FI FIC20230032C patent/FIC20230032I1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012MN02262A (en) | ||
| WO2011027222A3 (en) | Immunogenic compositions including tlr activity modulators | |
| WO2012075040A3 (en) | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES | |
| EP4253395A3 (en) | Processes for the preparation of carbohydrate conjugated rna agents | |
| WO2012129112A3 (en) | Use of intracellular enzymes for the release of covalently linked bioactives | |
| WO2012077950A3 (en) | Hyaluronic acid-protein conjugate and method for preparing same | |
| MX2012002654A (en) | Compounds and compositions as tlr activity modulators. | |
| MX350200B (en) | Human antibodies and antibody-drug conjugates against cd74. | |
| WO2013013013A3 (en) | Compositions and methods for producing modified glycoproteins | |
| WO2012099805A3 (en) | Nanoparticle based immunological stimulation | |
| MY161127A (en) | Enhanced soluble c5 saccharide yields | |
| PH12015500243A1 (en) | Glycoconjugation processes and compositions | |
| JO3065B1 (en) | Compounds and compositions as tlr activity modulators | |
| WO2011146518A3 (en) | Pegylated c-peptide | |
| IN2012DN02645A (en) | ||
| AU2011274619A8 (en) | miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway | |
| HK1216850A1 (en) | Anti-ntb-a antibodies and related compositions and methods | |
| BR112014024282A2 (en) | bradykinin b1 receptor binding antibodies | |
| WO2009135165A3 (en) | Small humanin-like peptides | |
| MX2017001898A (en) | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes. | |
| MX2012010448A (en) | Carbohydrate-polyamino acid-drug conjugates. | |
| WO2012064709A3 (en) | Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity | |
| WO2011112566A3 (en) | Basigin binding proteins | |
| PH12013500143A1 (en) | A method of treating alzheimer`s disease | |
| WO2012004013A3 (en) | Glucosinolate transporter protein and uses thereof |